Histidine

Histidine

SCHEMBL6426902

C[C@@H](O)[C@H](N)C(=O)O.N[C@@H](Cc1c[nH]cn1)C(=O)O

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.40
CYP3A4 P08684 1/20 0.40
CYP1A2 P05177 1/20 0.39
GRIA2 P42262 7/20 0.38
GRIA1 P42261 6/20 0.38
GRIA3 P42263 6/20 0.38
GRIA4 P48058 6/20 0.38
ALPI P09923 1/20 0.36
PKM P14618 1/20 0.36
PTGS1 P23219 1/20 0.36
XIAP P98170 1/20 0.36
GRIK1 P39086 3/20 0.34
GRIK2 Q13002 2/20 0.34
GRIK3 Q13003 2/20 0.34
GRIK4 Q16099 2/20 0.34
GRIK5 Q16478 2/20 0.34
HSD17B10 Q99714 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidine SCHEMBL668807 1.00 SLC7A5 (0.40) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL28805947 1.00 SLC7A5 (0.40) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL6426901 1.00 SLC7A5 (0.40) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL27597223 0.97 SLC7A5 (0.38) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL6724968 0.97 SLC7A5 (0.38) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL6947397 0.95 SLC7A5 (0.37) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL27504981 0.95 SLC7A5 (0.37) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL1061772 0.91 SLC7A5 (0.43) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL1061774 0.91 SLC7A5 (0.43) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL1537307 0.91 SLC7A5 (0.43) SLC7A5CYP3A4CYP1A2GRIA2GRIA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2793932-B1 CTP-BASED INSULIN ANALOGS FOR TREATMENT OF DIABETES UNIV INDIANA RES & TECH CORP (US) 2018-10-03 EP claimed
US-20160184271-A1 Amino Acid Composition for Use in the Treatment of a PDD N. V. NUTRICIA (NL) 2016-06-30 US disclosed
EP-3016647-A1 AMINO ACID COMPOSITION FOR USE IN THE TREATMENT OF A PDD N.V. Nutricia (NL) 2016-05-11 EP disclosed
WO-2015002537-A1 AMINO ACID COMPOSITION FOR USE IN THE TREATMENT OF A PDD N.V. NUTRICIA (NL) 2015-01-08 WO disclosed
WO-2015002527-A1 AMINO ACID COMPOSITION FOR USE IN THE TREATMENT OF A PDD N.V. NUTRICIA (NL) 2015-01-08 WO disclosed
WO-2013042140-A2 NON ANTIBIOTIC,NON PEPTIDE COMPOUNDS FOR ANTIBIOTIC EFFICACY & SAFETY ENHANCEMENT CHAUDHARY MANU (IN) 2013-03-28 WO disclosed
US-20050192460-A1 Process for preparing amino acid esters and their acid addition salts GOLDSCHMIDT GMBH (DE) 2005-09-01 US disclosed
EP-1150709-A2 ANTI-MICROBIAL AGENTS, DIAGNOSTIC REAGENTS, AND VACCINES BASED ON APICOMPLEXAN PARASITE COMPONENTS Mcleod, Rima W. (US) 2001-11-07 EP disclosed
WO-2000066154-A2 ANTI-MICROBIAL AGENTS, DIAGNOSTIC REAGENTS, AND VACCINES BASED ON UNIQUE APICOMPLEXAN PARASITE COMPONENTS ARCH DEVELOPMENT CORPORATION (US) 2000-11-09 WO disclosed
EP-0546108-A4 PRO-DRUGS FOR CCK ANTAGONISTS 1993-09-22 EP disclosed
EP-0546108-A1 PRO-DRUGS FOR CCK ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1993-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192460-A1 Process for preparing amino acid esters and their acid addition salts BCAT1, BCAT2, MAX SLC7A5 40/4885CYP3A4 1066/4885CYP1A2 3368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.